Barthwal M S, Marwah V, Chopra M, Garg Y, Tyagi R, Kishore K, Vijay A, Dutta V, Katoch C D S, Singh S, Bhattacharya D
Indian J Chest Dis Allied Sci. 2016 Jan-Mar;58(1):17-20.
Pleural fluid loculations due to complicated parapneumonic effusion (CPE), empyema, tubercular effusion and traumatic hemothorax can be managed either by video-assisted thoracoscopic surgery (VATS) or intrapleural ibrinolytic therapy (IPFT). The former is more invasive, not easily available and is also more expensive. On the other hand, IPFT is less invasive, cheaper, easily accessible and if used early, in loculated pleural collections, break loculations and early pleural peel, thereby facilitating pleural space drainage.
To study the efficacy of IPFT in facilitating pleural space drainage in loculated pleural collections of diverse aetiologies.
A five-year retrospective, observational study of 200 patients, with loculated pleural collections and failed tube drainage and managed with IPFT was carried out. Responders were defined as those with significant volume of fluid drained and significant radiological resolution.
There were 106 (53%) cases of CPE, 59 (29.5%) cases of tubercular effusion, 23 (11.5%) cases of empyema and 12 (6%) cases of hemothorax. Responders were 148 (74%) in number. The distribution of responders as per type of loculated pleural collection was as follows: CPE 88 (83%), tubercular 37 (62.7%), empyema 14 (60.8%) and traumatic hemothorax 11 (91.6%). The adverse effects were mild and included chest pain in six patients and low-grade transient fewer in three cases.
Intrapleural fibrinolytic therapy is a safe and cost-effective option in the management of selected patients with loculated pleural effusions.
因复杂性类肺炎性胸腔积液(CPE)、脓胸、结核性胸腔积液和创伤性血胸导致的胸腔积液分隔,可通过电视辅助胸腔镜手术(VATS)或胸腔内纤维蛋白溶解疗法(IPFT)进行处理。前者侵入性更强,不易实施且费用更高。另一方面,IPFT侵入性较小、费用更低、更容易实施,并且如果早期用于包裹性胸腔积液,可打破分隔并早期形成胸膜剥脱,从而促进胸腔引流。
研究IPFT在促进不同病因的包裹性胸腔积液胸腔引流中的疗效。
对200例有包裹性胸腔积液且胸腔闭式引流失败并接受IPFT治疗的患者进行了一项为期五年的回顾性观察研究。有反应者定义为胸腔引流量显著且影像学有显著改善者。
CPE患者106例(53%),结核性胸腔积液患者59例(29.5%),脓胸患者23例(11.5%),血胸患者12例(6%)。有反应者共148例(74%)。按包裹性胸腔积液类型划分的有反应者分布如下:CPE 88例(83%),结核性37例(62.7%),脓胸14例(60.8%),创伤性血胸11例(91.6%)。不良反应轻微,包括6例患者出现胸痛,3例患者出现轻度短暂发热。
胸腔内纤维蛋白溶解疗法在治疗部分包裹性胸腔积液患者时是一种安全且具有成本效益的选择。